You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

de Novo Activated B-cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

ddcfDNA in Kidney Transplant Recipients

Recruiting
  • Kidney Transplant Rejection
  • AlloSeq cfDNA
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Aug 22, 2023

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Frankfurt, Germany
    Department of Medicine, Hematology and Oncology, Goethe Universi
Sep 24, 2023

Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Trial in Tianjin (Vincristine, Daunorubicin, Cyclophosphamide)

Recruiting
  • Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 13, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Lymphoma, Lymphoma, B-Cell, Immune System Diseases Trial in Chapel Hill (iC9-CAR19 T cells, Bendamustine, Fludarabine)

Recruiting
  • Lymphoma
  • +4 more
  • iC9-CAR19 T cells
  • +4 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))

Not yet recruiting
  • Leukemia
  • +12 more
  • Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
  • (no location specified)
Mar 20, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Kidney Transplantation Trial in Baltimore, Livingston, New York (TCD601)

Recruiting
  • Kidney Transplantation
  • TCD601
  • San Francisco, California
  • +4 more
Oct 28, 2022

High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

Not yet recruiting
  • High-Risk de Novo Multiple Myeloma
  • Badalona, Spain
  • +9 more
Apr 27, 2023

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Salvador, Bahia, Brazil
    • +9 more
    Jul 24, 2023

    Kidney Transplantation Trial in United States (TCD601)

    Not yet recruiting
    • Kidney Transplantation
    • TCD601
    • Chicago, Illinois
    • +4 more
    Jun 13, 2022

    Lymphoma, B-Cell Trial in Belgium, France (Valemetostat tosylate)

    Recruiting
    • Lymphoma, B-Cell
    • Valemetostat tosylate
    • Bruges, Belgium
    • +21 more
    Jan 9, 2023

    Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

    Recruiting
    • Non-Hodgkin's Lymphoma
    • +2 more
    • CD19.CAR-CD28Z T Cells - dose escalation 2
    • CD19.CAR-CD28Z T Cells - dose escalation 1
    • Houston, Texas
    • +1 more
    Feb 10, 2022

    B-cell Lymphoma Trial in Israel, Puerto Rico, Turkey (ABBV-623, ABBV-992)

    Terminated
    • B-cell Lymphoma
    • Ramat Gan, Tel-Aviv, Israel
    • +4 more
    Feb 2, 2023

    Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin Trial in Worldwide (JNJ-67856633, Ibrutinib)

    Active, not recruiting
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • Lymphoma, Non-Hodgkin
    • Copenhagen, Denmark
    • +9 more
    Jan 27, 2023

    Course of COVID-19 in Prior, Ongoing or de Novo ITP. Evaluation

    Recruiting
    • Immune Thrombocytopenia
    • +3 more
      • Brescia, Italy
      • +7 more
      Aug 24, 2022

      NSCLC Trial in Guangzhou (Osimertinib, Savolitinib)

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Guangzhou, Guangdong, China
        Guangdong Lung Cancer Institute, Guangdong General Hospital, Gua
      Dec 6, 2021

      B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

      Recruiting
      • B-ALL
      • +10 more
      • 131-I Apamistamab
      • CAR T-cell
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Mar 7, 2022

      Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)

      Recruiting
      • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
      • Tianjin, China
        Institute of Hematology & Blood Diseases Hospital
      Oct 21, 2022

      Non-hodgkin Lymphoma, B Cell Trial in Switzerland (ctDNA detection)

      Not yet recruiting
      • Non-hodgkin Lymphoma, B Cell
      • ctDNA detection
      • Aarau, Switzerland
      • +12 more
      Oct 18, 2023

      ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

      Active, not recruiting
      • ALK-Positive Large B-Cell Lymphoma
      • +34 more
      • Phoenix, Arizona
      • +32 more
      Jan 3, 2023